Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

New European real-world audit data provides additional information on the effectiveness of Zebinix® (eslicarbazepine acetate) for the treatment of partial-onset epilepsy in adults

Eisai
Posted on: 13 Dec 17
  • Results from the pooled analysis presented at the American Epilepsy Society Annual Meeting 2017 in Washington DC, US.[i],[ii],[iii]

 

Porto, Portugal | Hatfield, UK | 13 December 2017 – Bial and Eisai have announced new real-world audit data presented at the American Epilepsy Society (AES) Annual Meeting 2017, which add to the existing clinical trials examining the effectiveness and tolerability of Zebinix® (eslicarbazepine acetate). These data assess the real-world effectiveness, safety and tolerability of eslicarbazepine acetate when used as monotherapy in patients with partial-onset seizures, following conversion from previous treatment with carbamazepine or oxcarbazepine and when treated with ≤1200 or >1200 mg/day eslicarbazepine acetate.1,2,3

 

Euro-Esli, an exploratory pooled analysis of data from 14 European clinical practice studies including 2,058 patients aged 14-88 years old with partial-onset seizures (POS), with or without secondary generalization, examined the real world use of eslicarbazepine acetate as monotherapy, as well as adjunctive therapy, for POS in clinical practice.

 

“Euro-Esli study offered data of >200 patients with eslicarbazepine acetate in monotherapy, where it proved to be an effective and tolerable option,” says Dr Vicente Villanueva, Neurologist and Epileptologist, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

 

The Euro-Esli study also showed that eslicarbazepine acetate was efficacious and generally well tolerated in patients switching from carbamazepine or oxcarbazepine in clinical practice.1 A further abstract, examining a different Euro-Esli data set, explored the effectiveness, safety and tolerability of eslicarbazepine acetate in patients with partial-onset seizures treated with ≤1200 or >1200 mg/day.2

 

Epilepsy is one of the most common neurological conditions in the world, affecting approximately fifty million people in Europe. [iv] It is defined as either: (1) the occurrence of two or more unprovoked seizures >24 hours apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures occurring over the next 10 years that is similar to the general recurrence risk (at least 60%) after two unprovoked seizures; (3) diagnosis of an epilepsy syndrome.[v] Depending on the type, seizures may involve one part of the body or the whole body, and may affect consciousness. Epilepsy has many possible causes but sometimes the cause is unknown.[vi]

 

“Real-world data explores the impact of a treatment in a real-life environment and these data improve our knowledge and understanding around the use of eslicarbazepine acetate, reinforcing BIAL’s commitment to developing and delivering beneficial treatment options for people living with epilepsy.” comments António Portela, CEO of BIAL.

 

“We are committed to the development of our anti-epileptic drug product portfolio, and Eisai continues to invest in real world evidence which will help us ensure we are addressing the diversity of epilepsy patients, which may help improve their quality of life,” comments Neil West, Vice President EMEA, Global Neurology Business Unit at Eisai.

 

In Europe eslicarbazepine acetate is indicated as:

  • monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in

adults with newly diagnosed epilepsy;

  • adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset

seizures with or without secondary generalisation.[vii]

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 13/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.